Research advances in Coronavirus Disease 2019 and rheumatoid arthritis

YANG Yekun; QIAN Jie

doi:10.7619/jcmp.20214086

Journal of Clinical Medicine in Practice > 2021 > 25(23): 115-119,123. > DOI: 10.7619/jcmp.20214086

YANG Yekun, QIAN Jie. Research advances in Coronavirus Disease 2019 and rheumatoid arthritis[J]. Journal of Clinical Medicine in Practice, 2021, 25(23): 115-119,123. DOI: 10.7619/jcmp.20214086

Citation:

YANG Yekun, QIAN Jie. Research advances in Coronavirus Disease 2019 and rheumatoid arthritis[J]. Journal of Clinical Medicine in Practice, 2021, 25(23): 115-119,123. DOI: 10.7619/jcmp.20214086

Citation:

YANG Yekun, QIAN Jie. Research advances in Coronavirus Disease 2019 and rheumatoid arthritis[J]. Journal of Clinical Medicine in Practice, 2021, 25(23): 115-119,123. DOI: 10.7619/jcmp.20214086

PDF (765 KB)

Research advances in Coronavirus Disease 2019 and rheumatoid arthritis

YANG Yekun,
QIAN Jie^,

Department of Rheumatology and Immunology,Affiliated Hospital of Nantong University,Nantong,Jiangsu,226001

More Information

Received Date: October 17, 2021
Available Online: December 13, 2021
Published Date: December 14, 2021

Graphical Abstract

Abstract

Abstract

Rheumatoid arthritis(RA) is an autoimmune disease characterized by chronic synovial inflammation,which eventually leads to different degrees of bone and cartilage erosion,even disability of joint.The patients of Coronavirus Disease 2019(COVID-19) can have musculoskeletal symptoms,and the mortality rate of critical patients is high.Cytokines play an important role in the pathogenesis of RA and COVID-19,the exact mechanism of which is unknown,and commonly used drugs of RA may guide the treatment of COVID-19.This article mainly reviewed the correlation between COVID-19 and RA in order to further improve the understanding of thepathogenesis,clinical manifestations,and treatment drugs of the disease and improve patients' outcomes.
- Coronavirus Disease 2019,
- rheumatoid arthritis,
- cytokine storm,
- treatment drugs

FullText(HTML)

References (51)

References

[1]	SMOLEN J S,ALETAHA D,BARTON A.Rheumatoid arthritis[J].Nat Rev Dis Primers,2018,4: 18001. doi: 10.1038/nrdp.2018.1
[2]	JOO Y B,LIM Y H,KIM K J,et al.Respiratory viral infections and the risk of rheumatoid arthritis[J].Arthritis Res Ther,2019,21(1): 199. doi: 10.1186/s13075-019-1977-9
[3]	HOFFMANN M,KLEINE-WEBER H,SCHROEDER S,et al.SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J].Cell,2020,181(2): 271-280. doi: 10.1016/j.cell.2020.02.052
[4]	ZHAO Y,ZHAO Z,WANG Y,et al.Single-cell RNA expression profiling of ACE2,the receptor of SARS-CoV-2[J].Am J Respir Crit Care Med,2020,202(5): 756-759. doi: 10.1164/rccm.202001-0179LE
[5]	TERENZI R,MANETTI M,ROSA I,et al.Angiotensin Ⅱ type 2 receptor (AT2R) as a novel modulator of inflammation in rheumatoid arthritis synovium[J].Sci Rep,2017,7(1): 13293. doi: 10.1038/s41598-017-13746-w
[6]	WU Y,LI M,ZENG J,et al.Differential expression of renin-angiotensin system-related components in patients with rheumatoid arthritis and osteoarthritis[J].Am J Med Sci,2020,359(1): 17-26. doi: 10.1016/j.amjms.2019.10.014
[7]	HIRANO T,MURAKAMI M.COVID-19: a new virus,but a familiar receptor and cytokine release syndrome[J].Immunity,2020,52(5): 731-733. doi: 10.1016/j.immuni.2020.04.003
[8]	靳云洲,李明芳,郑胜,等.新型冠状病毒肺炎患者不同病情状态下淋巴细胞、白细胞介素-6及炎症指标的变化[J].实用临床医药杂志,2020,24(6): 1-4.
[9]	LAI Q,SPOLETINI G,BIANCO G,et al.SARS-CoV2 and immunosuppression: a double-edged sword[J].Transpl Infect Dis,2020,22(6): e13404. http://journals.lww.com/anesthesia-analgesia/Fulltext/2020/10000/Human_Leukocyte_Antigen_DR_Deficiency_and.1.aspx
[10]	ELEMAM N M,HANNAWI S,MAGHAZACHI A A.Role of chemokines and chemokine receptors in rheumatoid arthritis[J].Immunotargets Ther,2020,9: 43-56. doi: 10.2147/ITT.S243636
[11]	MANGALMURTI N,HUNTER C A.Cytokine storms: understanding COVID-19[J].Immunity,2020,53(1): 19-25. doi: 10.1016/j.immuni.2020.06.017
[12]	MARKS M,MARKS J L.Viral arthritis[J].Clin Med Lond Engl,2016,16(2): 129-134.
[13]	MEMISH Z A,PERLMAN S,VAN KERKHOVE M D,et al.Middle East respiratory syndrome[J].Lancet,2020,395(10229): 1063-1077. doi: 10.1016/S0140-6736(19)33221-0
[14]	CIAFFI J,MELICONI R,RUSCITTI P,et al.Rheumatic manifestations of COVID-19: a systematic review and meta-analysis[J].BMC Rheumatol,2020,4: 65. doi: 10.1186/s41927-020-00165-0
[15]	HYLDGAARD C,ELLINGSEN T,HILBERG O,et al.Rheumatoid arthritis-associated interstitial lung disease: clinical characteristics and predictors of mortality[J].Respiration,2019,98(5): 455-460. doi: 10.1159/000502551
[16]	DAI Y,WANG W,YU Y,et al.Rheumatoid arthritis-associated interstitial lung disease: an overview of epidemiology,pathogenesis and management[J].Clin Rheumatol,2021,40(4): 1211-1220. doi: 10.1007/s10067-020-05320-z
[17]	WOOTTON S C,KIM D S,KONDOH Y,et al.Viral infection in acute exacerbation of idiopathic pulmonary fibrosis[J].Am J Respir Crit Care Med,2011,183(12): 1698-1702. doi: 10.1164/rccm.201010-1752OC
[18]	FONSECA M,SUMMER R,ROMAN J.Acute exacerbation of interstitial lung disease as a sequela of COVID-19 pneumonia[J].Am J Med Sci,2021,361(1): 126-129. doi: 10.1016/j.amjms.2020.08.017
[19]	HUANG H,ZHANG M,CHEN C,et al.Clinical characteristics of COVID-19 in patients with preexisting ILD: a retrospective study in a single center in Wuhan,China[J].J Med Virol,2020,92(11): 2742-2750. doi: 10.1002/jmv.26174
[20]	HUERTAS A,MONTANI D,SAVALE L,et al.Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?[J].Eur Respir J,2020,56(1): 2001634. doi: 10.1183/13993003.01634-2020
[21]	ACKERMANN M,VERLEDEN S E,KUEHNEL M,et al.Pulmonary vascular endothelialitis,thrombosis,and angiogenesis in covid-19[J].N Engl J Med,2020,383(2): 120-128. doi: 10.1056/NEJMoa2015432
[22]	MERONI P L,ZAVAGLIA D,GIRMENIA C.Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying anti-rheumatic drugs[J].Clin Exp Rheumatol,2018,36(2): 317-328. http://d.wanfangdata.com.cn/periodical/ChlQZXJpb2RpY2FsRW5nTmV3UzIwMjEwMzAyEiBjZDE1NTcyOThiZTQ4MGUyN2NkYTcwYjdkYzI3ZTQ4MxoIbHhqOTN2amk%3D
[23]	AKIYAMA S,HAMDEH S,MICIC D,et al.Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis[J].Ann Rheum Dis,2020,[Epub ahead of print].
[24]	JUNG Y,KWON M,CHOI H G.Association between previous rheumatoid arthritis and COVID-19 and its severity: a nationwide cohort study in South Korea[J].BMJ Open,2021,11(10): e054753. doi: 10.1136/bmjopen-2021-054753
[25]	QUARTUCCIO L,VALENT F,PASUT E,et al.Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: a population-based study in the first two months of COVID-19 outbreak in Italy[J].Joint Bone Spine,2020,87(5): 439-443. doi: 10.1016/j.jbspin.2020.05.003
[26]	FITZGERALD G A.Misguided drug advice for COVID-19[J].Science,2020,367(6485): 1434. http://www.researchgate.net/publication/340074598_Misguided_drug_advice_for_COVID-19
[27]	GIANFRANCESCO M,HYRICH K L,AL-ADELY S,et al.Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry[J].Ann Rheum Dis,2020,79(7): 859-866. doi: 10.1136/annrheumdis-2020-217871
[28]	MIKULS T R,JOHNSON S R,FRAENKEL L,et al.American college of rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 3[J].Arthritis Rheumatol,2021,73(2): e1-e12. doi: 10.1002/art.41889
[29]	FANG L,KARAKIULAKIS G,ROTH M.Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection[J].Lancet Respir Med,2020,8(4): e21. doi: 10.1016/S2213-2600(20)30116-8
[30]	LITTLE P.Non-steroidal anti-inflammatory drugs and covid-19[J].BMJ,2020,368: m1185. http://www.sciencedirect.com/science/article/pii/S0040595720300925
[31]	RECOVERY COLLABORATIVE GROUP,HORBY P,LIM W S,et al.Dexamethasone in hospitalized patients with covid-19[J].N Engl J Med,2021,384(8): 693-704. doi: 10.1056/NEJMoa2021436
[32]	ROCHWERG B,AGARWAL A,SIEMIENIUK R A,et al.A living WHO guideline on drugs for covid-19[J].BMJ Clin Res Ed,2020,370: m3379. http://www.bmj.com/content/370/bmj.m3379.short
[33]	FAVALLI E G,BUGATTI S,KLERSY C,et al.Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis[J].Arthritis Res Ther,2020,22(1): 290. doi: 10.1186/s13075-020-02395-6
[34]	SIEMIENIUK R A,BARTOSZKO J J,GE L,et al.Drug treatments for covid-19: living systematic review and network meta-analysis[J].BMJ,2020,370: m2980. http://www.bmj.com/content/370/bmj.m2980
[35]	FROHMAN E M,VILLEMARETTE-PITTMAN N R,CRUZ R A,et al.Part Ⅱ.High-dose methotrexate with leucovorin rescue for severe COVID-19: An immune stabilization strategy for SARS-CoV-2 induced 'PANIC' attack[J].J Neurol Sci,2020,415: 116935. doi: 10.1016/j.jns.2020.116935
[36]	HU K,WANG M,ZHAO Y,et al.A small-scale medication of leflunomide as a treatment of COVID-19 in an open-label blank-controlled clinical trial[J].Virol Sin,2020,35(6): 725-733. doi: 10.1007/s12250-020-00258-7
[37]	KIM J W,KWAK S G,LEE H,et al.Baseline use of hydroxychloroquine or immunosuppressive drugs and the risk of coronavirus disease 2019[J].Korean J Intern Med,2021,[Epub ahead of print].
[38]	FREDI M,CAVAZZANA I,MOSCHETTI L,et al.COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study[J].Lancet Rheumatol,2020,2(9): e549-e556. doi: 10.1016/S2665-9913(20)30169-7
[39]	VEIGA V C,PRATS J A G G,FARIAS D L C,et al.Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial[J].BMJ,2021,372: n84. http://www.bmj.com/content/372/bmj.n84.abstract
[40]	FELDMANN M,MAINI R N,WOODY J N,et al.Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed[J].Lancet,2020,395(10234): 1407-1409. doi: 10.1016/S0140-6736(20)30858-8
[41]	BACHILLER-CORRAL J,BOTEANU A,GARCIA-VILLANUEVA M J,et al.Risk of severe COVID-19 infection in patients with inflammatory rheumatic diseases[J].J Rheumatol,2021,48(7): 1098-1102. doi: 10.3899/jrheum.200755
[42]	徐东,曾小峰.阿巴西普治疗类风湿关节炎的机制及临床研究进展[J].中华风湿病学杂志,2020,24(10): 702-709. doi: 10.3760/cma.j.c141217-20200427-00177
[43]	CANTINI F,NICCOLI L,MATARRESE D,et al.Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact[J].J Infect,2020,81(2): 318-356. http://www.sciencedirect.com/science/article/pii/S0163445320302280
[44]	CAO Y,WEI J,ZOU L,et al.Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter,single-blind,randomized controlled trial[J].J Allergy Clin Immunol,2020,146(1): 137-146. doi: 10.1016/j.jaci.2020.05.019
[45]	曹雪涛.新型冠状病毒肺炎及新发传染病之免疫学研究[J].中华医学杂志,2021,101(1): 1-6. doi: 10.3760/cma.j.cn112137-20201211-03336
[46]	WILLIAMSON E J,WALKER A J,BHASKARAN K,et al.Factors associated with COVID-19-related death using OpenSAFELY[J].Nature,2020,584(7821): 430-436. doi: 10.1038/s41586-020-2521-4
[47]	CHENG C,LI C,ZHAO T,et al.COVID-19 with rheumatic diseases: a report of 5 cases[J].Clin Rheumatol,2020,39(7): 2025-2029. doi: 10.1007/s10067-020-05160-x
[48]	SOY M,KESER G,ATAGVNDVZ P,et al.Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment[J].Clin Rheumatol,2020,39(7): 2085-2094. doi: 10.1007/s10067-020-05190-5
[49]	WANG B,SHAO X,WANG D,et al.Vaccinations and risk of systemic lupus erythematosus and rheumatoid arthritis: a systematic review and meta-analysis[J].Autoimmun Rev,2017,16(7): 756-765. doi: 10.1016/j.autrev.2017.05.012
[50]	FURER V,EVIATAR T,ZISMAN D,et al.Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study[J].Ann Rheum Dis,2021,80(10): 1330-1338. doi: 10.1136/annrheumdis-2021-220647
[51]	BRAUN-MOSCOVICI Y,KAPLAN M,BRAUN M,et al.Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2[J].Ann Rheum Dis,2021,80(10): 1317-1321. doi: 10.1136/annrheumdis-2021-220503

[1]	FANG Liya, LIU Yuanyuan, LIU Jiahao, LI Jiawei, ZENG Pei, GUO Jin. Research progress in microRNAs as potential biomarkers in temporal lobe epilepsy[J]. Journal of Clinical Medicine in Practice, 2025, 29(1): 130-135. DOI: 10.7619/jcmp.20243845
[2]	SHAN Xiaoli, CHI Runze, YU Xin, LI Bingong. Correlation between left atrial diameter and renal function in patients with atrial fibrillation[J]. Journal of Clinical Medicine in Practice, 2024, 28(9): 34-39. DOI: 10.7619/jcmp.20240497
[3]	WANG Tianwei, TANG Chengbin, JIANG Wei, YU Hailong, SHAO Jun, YUAN Jing. Research progress on early biomarkers of cardiac surgery-associated acute kidney injury[J]. Journal of Clinical Medicine in Practice, 2024, 28(3): 131-139, 143. DOI: 10.7619/jcmp.20232815
[4]	ZHANG Chen, YANG Zhen, ZHAO Yi, YANG Xiaoli. Prognostic biomarkers of multimodal imaging in central serous chorioretinopathy[J]. Journal of Clinical Medicine in Practice, 2023, 27(4): 133-137, 143. DOI: 10.7619/jcmp.20223176
[5]	ZHOU Dan, LI Xiuli, HU Hao, ZHAI Shaopeng, WANG Manxia. Clinical value of diagnostic biomarkers for patent foramen ovale-associated stroke[J]. Journal of Clinical Medicine in Practice, 2023, 27(2): 134-138. DOI: 10.7619/jcmp.20222935
[6]	YOU Jing, HE Miao, ZHOU Feng, LI Weirong. Research progress on roles of blood biomarkers in etiological classification of ischemic stroke[J]. Journal of Clinical Medicine in Practice, 2022, 26(6): 118-122. DOI: 10.7619/jcmp.20214524
[7]	LIU Jiujiang, LIN Hua. Research progress of serum biomarkers in acute respiratory distress syndrome[J]. Journal of Clinical Medicine in Practice, 2021, 25(23): 124-128. DOI: 10.7619/jcmp.20213576
[8]	ZHANG Naiying, LI Bo. Detection of serum biomarkers related to type 2 diabetes mellitus and their analysis[J]. Journal of Clinical Medicine in Practice, 2020, 24(21): 79-81. DOI: 10.7619/jcmp.202021023
[9]	ZHOU Lei, GAO Zhanqiang. Analysis on coagulation indexes, biochemical indexes and occurrence of venous thrombosis in patients with heart failure and atrial fibrillation[J]. Journal of Clinical Medicine in Practice, 2020, 24(18): 50-53. DOI: 10.7619/jcmp.202018014
[10]	WU Xiaoxia, YU Xinyue, HUANG Yin, LIU Peifang. Network-based analysis of blood metabolic biomarkers for stroke[J]. Journal of Clinical Medicine in Practice, 2020, 24(18): 1-6. DOI: 10.7619/jcmp.202018001

Cited By

Get Citation

PDF

XML

Article views (1133) PDF downloads (63)

Turn off MathJax

Article Contents

Abstract

References

Research advances in Coronavirus Disease 2019 and rheumatoid arthritis

Abstract

References

Related Articles

Catalog

Research advances in Coronavirus Disease 2019 and rheumatoid arthritis

Abstract

References

Related Articles

Catalog

Export File

Citation

Format

Content